Effectiveness and Safety Outcomes of Standard of Care (SOC) Lisocabtagene Maraleucel (liso-cel) in Patients (Pts) with Relapsed or Refractory (R/R) Transformed Large B-Cell Lymphoma (tLBCL): Results from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry
Iris Isufi(Yale University), Sairah Ahmed(The University of Texas MD Anderson Cancer Center), Farah Toron(Bristol-Myers Squibb (United Kingdom)), David Bernasconi(Bristol-Myers Squibb (United States)), Matthew J. Frigault(Harvard University), Charalambos Andreadis(University of California, San Francisco), Marcelo C. Pasquini(Cleveland Clinic), Jennifer L. Crombie(Dana-Farber Cancer Institute), Yi Lin, Soyoung Kim(Medical College of Wisconsin), Abu‐Sayeef Mirza(University of South Florida), Debasmita Roy(Bristol-Myers Squibb (United States)), Tracy Krimmel(Bristol-Myers Squibb (United States))
Cited by 1
Related Papers
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.1k
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
|Journal of Clinical Oncology|2020|782
Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19
|JAMA|2021|723
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes
|Journal of Clinical Oncology|2017|664